Xmas present for @RaceOncology and @Mason14
Leqvio approved by the FDA.
Gives a perspective of what non-cancer indications / applications an FTO inhibitor could potentially sell for.
- Peaks sales US $2B
- Buyout by Novartis for USD $9.7B in 2020 ( 4.85x peak sales )
- Precision / stratified approach to Cardiovascular diseases with a PCSK9 inhibitor
https://www.novartis.com/news/media...er-cholesterol-and-keep-it-low-two-doses-year
https://www.fiercepharma.com/market...id-pitfalls-amgen-regeneron-pcsk9-cholesterol
Xmas present for @RaceOncology and @Mason14 Leqvio approved by...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 26825 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 759 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |